SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

By
Andrea Surnit
June 9, 2026
5 min

Conexiant

At a Glance

Category	Detail
Condition
Key Mechanisms	Effects on glucose uptake in renal tumor cells, ketogenesis, autophagy, and glomerular hyperfiltration (not directly tested in this study).
Target Population
Care Setting

Key Highlights

SGLT2 inhibitors associated with a 40% lower hazard of kidney cancer compared to DPP-4 inhibitors, but findings are observational and require further validation.

Guideline-Based Recommendations

Diagnosis

Management

Consider SGLT2 inhibitors for type 2 diabetes management, noting potential association with lower kidney cancer risk, but further validation is needed.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Korean patients aged 20 to 79 years with type 2 diabetes.

SGLT2 inhibitors include dapagliflozin, empagliflozin, ertugliflozin, or ipragliflozin.

Clinical Best Practices

Use propensity score matching to compare treatment effects.
Consider the implications of prescribing patterns and glycemic control in observational studies.
Acknowledge limitations related to follow-up duration and potential undetected cancers.
Consider individual patient factors when prescribing.